News
Targeted viral therapy destroys breast cancer stem cells in preclinical experiments
A promising new treatment for breast cancer being developed at Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine (VIMM) has been shown in cell culture and in animal models to selectively kill cancer stem...
News
FDA obtains waiver from European Commission to facilitate export for U.S. pharmaceutical manufacturers
The U.S. Food and Drug Administration announced that the U.S. is now a "listed" countrydisclaimer icon with the European Commission (EC) so that U.S. companies need not obtain an export certificate from the FDA before shipping certain pharmaceutical products...
News
Aspirin may fight cancer by slowing DNA damage
Aspirin is known to lower risk for some cancers, and a new study led by a UC San Francisco scientist points to a possible explanation, with the discovery that aspirin slows the accumulation of DNA mutations in abnormal cells...
News
MedImmune, AstraZeneca’s biologics arm, and NGM Biopharmaceuticals announce agreement to discover and develop therapies for diabetes and obesity
AstraZeneca announced that MedImmune, its global biologics research and development arm, and NGM Biopharmaceuticals, Inc. have entered into an exclusive agreement to discover, develop and commercialise novel therapeutics from NGM's enteroendocrine cell (EEC) programme for the treatment of type...
News
Diabetes drug points the way to overcoming drug resistance in melanoma
Advanced metastatic melanoma is a disease that has proven difficult to eradicate. Despite the success of melanoma-targeting drugs, tumors inevitably become drug resistant and return, more aggressive than before. In the current issue of the...
News
Big multiple sclerosis breakthrough
A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients' immune systems' reactivity to myelin by 50 to 75 percent, according...
News
FDA grants Priority Review to Bristol-Myers Squibb and AstraZeneca’s Metreleptin
Bristol-Myers Squibb Company and AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has accepted and granted a Priority Review designation for the Biologics License Application (BLA) for metreleptin, an investigational agent for the treatment of metabolic disorders...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read